Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
STLE Annual MeetingSTLE Annual Meeting
Not Confirmed
Not Confirmed
17-21 May, 2026
Biogas AmericasBiogas Americas
Not Confirmed
Not Confirmed
18-21 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
STLE Annual MeetingSTLE Annual Meeting
Industry Trade Show
Not Confirmed
17-21 May, 2026
Biogas AmericasBiogas Americas
Industry Trade Show
Not Confirmed
18-21 May, 2026
Digital content
NEWS #PharmaBuzz
18 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/wuxi-apptec-recognized-as-a-top-performing-company-on-2026-dow-jones-best-in-class-world-index-302774184.html
18 May 2026
// FIRSTWORD PHARMA
30 Apr 2026
// ENDPOINTS
https://endpoints.news/xtl-bio-to-acquire-psychedelic-biotech-wuxi-apptecs-q1-revenue-rise/
18 Jan 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/wuxi-apptec-receives-double-a-rating-from-cdp-for-climate-change-and-water-security-leadership-302664053.html
04 Dec 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/after-dodging-biosecure-threat-wuxi-apptec-pentagons-crosshairs
20 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/wuxi-apptec-receives-frost--sullivans-2025-global-company-of-the-year-award-in-the-crdmo-industry-302620253.html
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Click Us!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37610
Submission : 2023-06-07
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36725
Submission : 2022-02-03
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38725
Submission : 2023-08-16
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36104
Submission : 2021-07-22
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32693
Submission : 2019-01-02
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33124
Submission : 2018-12-28
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34821
Submission : 2020-05-29
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37861
Submission : 2022-12-28
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37862
Submission : 2022-12-28
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38490
Submission : 2023-06-20
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
Nano-Mupirocin, an antibiotic targeting bacterial isoleucyl-tRNA synthetase, shows promise in treating Methicillin-Resistant Staphylococcus aureus (MRSA).
Lead Product(s): Nano-Mupirocin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibiotic
Recipient: Revium Rx
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2025
Lead Product(s) : Nano-Mupirocin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : Revium Rx
Deal Size : Inapplicable
Deal Type : Inapplicable
Revium Rx Progresses to Phase 1 for Nano-Mupirocin Against Antibiotic-Resistant Infections
Details : Nano-Mupirocin, an antibiotic targeting bacterial isoleucyl-tRNA synthetase, shows promise in treating Methicillin-Resistant Staphylococcus aureus (MRSA).
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 21, 2025
Details:
Through the partnership, Silo Pharma will advance the development of the SPU-16 for an early-stage study, a central nervous system homing peptide targeting multiple sclerosis.
Lead Product(s): SPU-16
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide, Unconjugated
Sponsor: Silo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 07, 2024
Lead Product(s) : SPU-16
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Silo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Silo Pharma Announces Partnership with Global CRO for CNS Homing Peptide
Details : Through the partnership, Silo Pharma will advance the development of the SPU-16 for an early-stage study, a central nervous system homing peptide targeting multiple sclerosis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
August 07, 2024
Details:
Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.
Lead Product(s): Resecabtagene Autoleucel
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Cabaletta Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 22, 2023
Lead Product(s) : Resecabtagene Autoleucel
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Cabaletta Bio
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 22, 2023
Details:
Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.
Lead Product(s): INT2104
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Interius BioTherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023
Lead Product(s) : INT2104
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Interius BioTherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
May 08, 2023
Details:
PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and motility.
Lead Product(s): PAS-004
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Recipient: Pasithea Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 18, 2023
Lead Product(s) : PAS-004
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Recipient : Pasithea Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and m...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 18, 2023
Details:
Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology
Details : Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 11, 2022
Details:
TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Sirona Biochem Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2022
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Sirona Biochem Corp
Deal Size : Undisclosed
Deal Type : Agreement
Details : TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 22, 2022
Details:
The partnership initially focusses on Chimeric’s two autologous CAR T-cell therapies for solid tumours: CHM 2101, currently in late preclinical for gastrointestinal cancers and CHM 1101 (CLTX CAR T), currently in single-site phase 1 for recurrent or progressive glioblastoma.
Lead Product(s): CHM 1101
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Recipient: Chimeric Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 12, 2022
Lead Product(s) : CHM 1101
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Chimeric Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Chimeric Enters Strategic Manufacturing Partnership With WuXi Advanced Therapies
Details : The partnership initially focusses on Chimeric’s two autologous CAR T-cell therapies for solid tumours: CHM 2101, currently in late preclinical for gastrointestinal cancers and CHM 1101 (CLTX CAR T), currently in single-site phase 1 for recurrent or pr...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 12, 2022
Details:
Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Orbit Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Orbit Discovery
Deal Size : Undisclosed
Deal Type : Partnership
Details : Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 07, 2022
Details:
The National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).
Lead Product(s): Orelabrutinib
Therapeutic Area: Neurology Brand Name: Hibruka
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: InnoCare Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2021
Lead Product(s) : Orelabrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : InnoCare Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Orelabrutinib Included in Priority Review by NMPA
Details : The National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic l...
Product Name : Hibruka
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE
WuXi AppTec is a supplier offers 29 products (APIs, Excipients or Intermediates).
Find Exatecan bulk with DMF offered by WuXi AppTec
Find Mafodotin [Usan] bulk with DMF offered by WuXi AppTec
Find MC-VC-PAB-MMAE bulk with DMF offered by WuXi AppTec
Find Monomethyl Auristatin E bulk offered by WuXi AppTec
Find 2'-OME U AMIDITE bulk offered by WuXi AppTec
Find 2' -MOE A(BZ) AMIDITE bulk offered by WuXi AppTec
Find 2'-MOE G(IBU) AMIDITE bulk offered by WuXi AppTec
Find MORPHOLINO GUANINE PHOSPHORAMIDOCHLORIDATE bulk offered by WuXi AppTec
Find WUXI ADHERENT HEK293T (WAHT) bulk offered by WuXi AppTec
Find 2'-OME A(BZ) AMIDITE bulk offered by WuXi AppTec
Find 2'-MOE T AMIDITE bulk offered by WuXi AppTec
Find CPG OLIGONUCLEOTIDE 1018 bulk offered by WuXi AppTec
Find PAYLOAD-LINKER VCMMAE bulk offered by WuXi AppTec
Find VAL-CIT-PAB-MMAE bulk offered by WuXi AppTec
Find 2'-OME G(IBU) AMIDITE bulk offered by WuXi AppTec
Find 2'-MOE MEC(BZ) AMIDITE bulk offered by WuXi AppTec
Find MORPHOLINO THYMINE PHOSPHORAMIDOCHLORIDATE bulk offered by WuXi AppTec
Find LENTIVIRAL VECTOR bulk offered by WuXi AppTec
Find CAS No 1613220-15-7 bulk offered by WuXi AppTec
Find Elexacaftor bulk offered by WuXi AppTec
Find Enavogliflozin bulk offered by WuXi AppTec
Find Ivacaftor bulk offered by WuXi AppTec
Find Orforglipron Calcium Hydrate bulk offered by WuXi AppTec
Find Roxadustat bulk offered by WuXi AppTec
Find Sparsentan bulk offered by WuXi AppTec
Find Telotristat Etiprate bulk offered by WuXi AppTec
Find Tezacaftor bulk offered by WuXi AppTec
Find Tirzepatide bulk offered by WuXi AppTec
Find Zanubrutinib bulk offered by WuXi AppTec
Share 
